Overexpressed human P-cadherin contributes to the malignancy of cancer cells6, 7, so a promising therapeutic strategy is to develop antibodies that inhibit the cell adhesion of P-cadherin, suppressing malignancy both in vitro and in vivo7, 9, 10. This evidence concerns the gene CDH3 and cancer.